Drugs / AloCELYVIR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05047276 | Oct 2021 → Jun 2023 | uveal melanoma | José María Piulats Rodríguez | Unknown | No outcome recorded |
| Phase 1/2 | NCT04758533 | Apr 2021 → Apr 2026 overdue | childhood medulloblastoma, diffuse intrinsic pontine glioma | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AloCelyvir | “Patients will received weekly infusion of AloCELYVIR during 8 weeks.” NCT04758533 ↗ |
| Modality | Cell therapy | “bone marrow-derived allogenic mesenchymal stem cells infected with an oncolytic Adenovirus” NCT04758533 ↗ |
| Route | Intravenous | “weekly intravenous infusions” NCT05047276 ↗ |